The MIMIGA Study is a Randomized, Double-blind, Placebo-controlled Crossover Trial Evaluating the Safety and Efficacy of SCFA vs. Placebo. Administered Orally Once Daily With Standard Care, it Aims to Prevent CKD Progression in Biopsy-proven IgA Nephropathy by Modulating the Gut Microbiome.
Clinical trial NCT07750249 · ENROLLING_BY_INVITATION
Trial details
- NCT number
- NCT07750249
- Sponsor
- University Hospital, Martin
- Status
- ENROLLING_BY_INVITATION
- Phase
- Early Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-03-01
- Primary completion
- 2028-12-31
- Enrollment
- 120
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.